# A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

> **NCT03069378** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Sarcoma
- Epithelioid Sarcoma
- Cutaneous Angiosarcoma

## Interventions

- **DRUG:** Talimogene Laherparepvec (T-VEC)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03069378
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-03
- **Primary completion:** 2025-07-22
- **Final completion:** 2026-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069378, "A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03069378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*